Bayer Corporate Newshttps://www.bayer.com02.11.2020 21:39:41 Bayer AG, Leverkusen, GermanyAll internationally relevant press releases from the Bayer Grouppublic://2020-06/Responsible Care (PDF, 372 KB).pdfBayer Corporate Newshttps://www.bayer.comENRivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularizationhttps://media.bayer.de/baynews/baynews.nsf/id/Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularizationhttps://media.bayer.de/baynews/baynews.nsf/id/Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularizationMon, 26.10.2020 13:30:00FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PADBayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapyhttps://media.bayer.de/baynews/baynews.nsf/id/Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapyhttps://media.bayer.de/baynews/baynews.nsf/id/Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapyMon, 26.10.2020 08:30:00Finerenone-significantly-reduced-renal-cardiovascular-outcomes-patients-chronic-kidney-disease-2https://media.bayer.de/baynews/baynews.nsf/id/Finerenone-significantly-reduced-renal-cardiovascular-outcomes-patients-chronic-kidney-disease-2https://media.bayer.de/baynews/baynews.nsf/id/Finerenone-significantly-reduced-renal-cardiovascular-outcomes-patients-chronic-kidney-disease-2Fri, 23.10.2020 16:30:00Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine